Deltex Medical (LON:DEMG) has taken on the UK distributorship of a non-invasive brain monitor to broaden its product range.
The oesophageal Doppler blood flow monitoring specialist has signed an exclusive deal with CAS Medical Systems’ FORE-SIGHT to sell its cerebral oximeter monitors in the UK and Ireland.
Used primarily in cardiac surgery, these monitors alert doctors when levels of oxygen in the brain reach dangerously high levels.
The UK market is worth £1mln annually with FORE-SIGHT accounting for a fifth of that in 2014.
CASMED is NASDAQ-listed and approximately two-thirds of its growth currently is in the US and it expects the tie-up with Deltex to boost UK sales.
Thomas Patton, CASMED’s president and chief executive, said: “With a sales channel to over 90% of major UK hospitals supported by a full national team of sales representatives and clinical support personnel, Deltex has excellent penetration and relationships in hospitals that are likely users of FORE-SIGHT."
Ewan Phillips, Deltex Medical's chief executive, said: "Cerebral oximetry is a complementary technology to our haemodynamic monitoring products."